PATH-13. MOLECULAR AND BIOLOGY CORRELATIVE RESULTS FROM THE PHASE 1B TRIAL OF UNESBULIN (PTC596) WITH RADIOTHERAPY IN CHILDREN NEWLY-DIAGNOSED WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)

Abstract BACKGROUND Within the CONNECT1702 trial of unesbulin (tubulin-binding agent causing BMI-1 modulation) with radiotherapy in patients with DIPG/HGG, tumor tissue was analyzed at diagnosis and/or autopsy for biology correlatives, enabling comprehensive, longitudinal molecular characterization....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2024-11, Vol.26 (Supplement_8), p.viii180-viii180
Hauptverfasser: Lazow, Margot, Baxter, Patricia, Kumar, Shiva Senthil, Mohamad, Maya, Mackay, Alan, Stanek, Joseph, Rodriguez, Diana, Palmer, Joshua, Leach, James, Mikael, Leonie, Thomas, Diana, Fuller, Christine, Boué, Daniel, Pierson, Christopher, Breneman, John, Li, Xiao-Nan, Salloum, Ralph, Ashley, David, de Blank, Peter, Hwang, Eugene, Leary, Sarah, Plant, Ashley, Fisher, Michael, Chi, Susan, Murala, Mythili, Weetall, Marla, Rance, Mark, Baird, John, D’Silva, Dhiren, O’Keefe, Kylie, Leonard, Jeffrey, Stewart, Clinton, Jones, Chris, Mardis, Elaine, Fouladi, Maryam, Drissi, Rachid
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page viii180
container_issue Supplement_8
container_start_page viii180
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 26
creator Lazow, Margot
Baxter, Patricia
Kumar, Shiva Senthil
Mohamad, Maya
Mackay, Alan
Stanek, Joseph
Rodriguez, Diana
Palmer, Joshua
Leach, James
Mikael, Leonie
Thomas, Diana
Fuller, Christine
Boué, Daniel
Pierson, Christopher
Breneman, John
Li, Xiao-Nan
Salloum, Ralph
Ashley, David
de Blank, Peter
Hwang, Eugene
Leary, Sarah
Plant, Ashley
Fisher, Michael
Chi, Susan
Murala, Mythili
Weetall, Marla
Rance, Mark
Baird, John
D’Silva, Dhiren
O’Keefe, Kylie
Leonard, Jeffrey
Stewart, Clinton
Jones, Chris
Mardis, Elaine
Fouladi, Maryam
Drissi, Rachid
description Abstract BACKGROUND Within the CONNECT1702 trial of unesbulin (tubulin-binding agent causing BMI-1 modulation) with radiotherapy in patients with DIPG/HGG, tumor tissue was analyzed at diagnosis and/or autopsy for biology correlatives, enabling comprehensive, longitudinal molecular characterization. METHODS Whole genome sequencing, RNA-sequencing, and Western blot analyses were performed on tumor, normal brain, and peripheral blood mononuclear cells (PBMCs). RESULTS Tumor tissue from diagnosis (n=11) and/or autopsy (n=7) was analyzed for 16 patients (DIPG=9; HGG=7). Western blot analyses demonstrated 1) BMI-1 overexpression in baseline tumor compared to normal brain and 2) primary on-target effect of BMI1-modulation causing M-phase mitotic arrest when comparing pre- and post-treated PBMCs (increased H3S10-phosphorylation). Among 9 DIPG patients, alterations in the following genes were identified: H3-3A (H3.3) (n=5), H3C2 (H3.1) (n=2, both with co-occurring ACVR1 and PIK3CA mutations), TP53 (n=5), ATRX (n=2), and PPM1D (n=2). Tumors from two longer DIPG survivors were H3.1-, ACVR1-mutant (overall survival [OS]=26 months) and MET-amplified (OS=18 months); one patient with H3.3K27M-DIPG had germline MSH6 mutation (Lynch syndrome) (OS=12.6 months). Among 7 HGG patients, alterations in the following genes were identified: H3-3A (n=5), TP53 (n=3), NF1 (n=3), PDGFRA (n=1), EGFR (n=1), and PIK3CA (n=1). A BRAFV600E mutation was observed in the thalamic HGG patient (H3.3K27M) with greatest progression-free survival (>23 months). Early leptomeningeal metastases occurred in one DIPG patient with BCOR alteration and one HGG patient, with MYCN amplification identified in the spinal metastasis, but not intracranial disease. From gene set enrichment analyses, pathways enriched in patients with longer survival included telomerase regulation and ATP synthesis, whereas pathways enriched in patients with shorter survival included interneuron development, neuron semaphorin signaling, and gamma aminobutyric signaling. CONCLUSIONS Comprehensive molecular profiling of diagnostic and post-mortem tumor tissue provides valuable early biological insight, elucidating potential genomic biomarkers predictive of outcome and response to M-phase alteration and BMI-1 modulation in DIPG/HGG.
doi_str_mv 10.1093/neuonc/noae165.0712
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_neuonc_noae165_0712</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noae165.0712</oup_id><sourcerecordid>10.1093/neuonc/noae165.0712</sourcerecordid><originalsourceid>FETCH-LOGICAL-c832-dee8daf0eb6024e6b3f26e45980a42c2f3571660d6d2dd371e2222e91c5b8db23</originalsourceid><addsrcrecordid>eNqNkUGPmzAQhWnVSt1u-wt6mWNyIItNcEhvjjFg1bGRMY1yQiQYqVWbrIL2sP--Toi01_rikWa-p_f0guAbihYoWsdPJ_dyPh2fTufOIZIsohXC74MHlOA4TFJCPtxmHKYJWn0KPo_j7yjCKCHo4V1YUVuGKF7AVkvOGkkNUJXBRmipiz0wbQyX1IqfHAyvG2lryI3egi05VCWtOaANWCOoBJ1Do3i9aaRQMKssS9ZkDjthSzA0E9ojhlZ78FtWCpkZrkDxndyHmaCF0jXPputM5HnjlYXywqoWDCqtrFAcCin0lsIsE1UxvxktRVGGhdd_W5ZFMf8O1PuttLFvdpmWkm60mdIobnfa_IBcGz83RodasXtoH0Awn-iWq4YZ00pxZudfgo9D92d0X-__Y2BzblkZeuwKhMc0xmHvXNp3Q-QOJMJLRw7xgIlbJus06pb4iIc4WSFCop70uO_jFXLYP7dGx-SQ9gccPwbxJHu8nMfx4ob2-fLrb3d5bVHUXgtvp8Lbe-HttXBPLSbq_PL8X8A_urGaKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>PATH-13. MOLECULAR AND BIOLOGY CORRELATIVE RESULTS FROM THE PHASE 1B TRIAL OF UNESBULIN (PTC596) WITH RADIOTHERAPY IN CHILDREN NEWLY-DIAGNOSED WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Lazow, Margot ; Baxter, Patricia ; Kumar, Shiva Senthil ; Mohamad, Maya ; Mackay, Alan ; Stanek, Joseph ; Rodriguez, Diana ; Palmer, Joshua ; Leach, James ; Mikael, Leonie ; Thomas, Diana ; Fuller, Christine ; Boué, Daniel ; Pierson, Christopher ; Breneman, John ; Li, Xiao-Nan ; Salloum, Ralph ; Ashley, David ; de Blank, Peter ; Hwang, Eugene ; Leary, Sarah ; Plant, Ashley ; Fisher, Michael ; Chi, Susan ; Murala, Mythili ; Weetall, Marla ; Rance, Mark ; Baird, John ; D’Silva, Dhiren ; O’Keefe, Kylie ; Leonard, Jeffrey ; Stewart, Clinton ; Jones, Chris ; Mardis, Elaine ; Fouladi, Maryam ; Drissi, Rachid</creator><creatorcontrib>Lazow, Margot ; Baxter, Patricia ; Kumar, Shiva Senthil ; Mohamad, Maya ; Mackay, Alan ; Stanek, Joseph ; Rodriguez, Diana ; Palmer, Joshua ; Leach, James ; Mikael, Leonie ; Thomas, Diana ; Fuller, Christine ; Boué, Daniel ; Pierson, Christopher ; Breneman, John ; Li, Xiao-Nan ; Salloum, Ralph ; Ashley, David ; de Blank, Peter ; Hwang, Eugene ; Leary, Sarah ; Plant, Ashley ; Fisher, Michael ; Chi, Susan ; Murala, Mythili ; Weetall, Marla ; Rance, Mark ; Baird, John ; D’Silva, Dhiren ; O’Keefe, Kylie ; Leonard, Jeffrey ; Stewart, Clinton ; Jones, Chris ; Mardis, Elaine ; Fouladi, Maryam ; Drissi, Rachid</creatorcontrib><description>Abstract BACKGROUND Within the CONNECT1702 trial of unesbulin (tubulin-binding agent causing BMI-1 modulation) with radiotherapy in patients with DIPG/HGG, tumor tissue was analyzed at diagnosis and/or autopsy for biology correlatives, enabling comprehensive, longitudinal molecular characterization. METHODS Whole genome sequencing, RNA-sequencing, and Western blot analyses were performed on tumor, normal brain, and peripheral blood mononuclear cells (PBMCs). RESULTS Tumor tissue from diagnosis (n=11) and/or autopsy (n=7) was analyzed for 16 patients (DIPG=9; HGG=7). Western blot analyses demonstrated 1) BMI-1 overexpression in baseline tumor compared to normal brain and 2) primary on-target effect of BMI1-modulation causing M-phase mitotic arrest when comparing pre- and post-treated PBMCs (increased H3S10-phosphorylation). Among 9 DIPG patients, alterations in the following genes were identified: H3-3A (H3.3) (n=5), H3C2 (H3.1) (n=2, both with co-occurring ACVR1 and PIK3CA mutations), TP53 (n=5), ATRX (n=2), and PPM1D (n=2). Tumors from two longer DIPG survivors were H3.1-, ACVR1-mutant (overall survival [OS]=26 months) and MET-amplified (OS=18 months); one patient with H3.3K27M-DIPG had germline MSH6 mutation (Lynch syndrome) (OS=12.6 months). Among 7 HGG patients, alterations in the following genes were identified: H3-3A (n=5), TP53 (n=3), NF1 (n=3), PDGFRA (n=1), EGFR (n=1), and PIK3CA (n=1). A BRAFV600E mutation was observed in the thalamic HGG patient (H3.3K27M) with greatest progression-free survival (&gt;23 months). Early leptomeningeal metastases occurred in one DIPG patient with BCOR alteration and one HGG patient, with MYCN amplification identified in the spinal metastasis, but not intracranial disease. From gene set enrichment analyses, pathways enriched in patients with longer survival included telomerase regulation and ATP synthesis, whereas pathways enriched in patients with shorter survival included interneuron development, neuron semaphorin signaling, and gamma aminobutyric signaling. CONCLUSIONS Comprehensive molecular profiling of diagnostic and post-mortem tumor tissue provides valuable early biological insight, elucidating potential genomic biomarkers predictive of outcome and response to M-phase alteration and BMI-1 modulation in DIPG/HGG.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noae165.0712</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii180-viii180</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Lazow, Margot</creatorcontrib><creatorcontrib>Baxter, Patricia</creatorcontrib><creatorcontrib>Kumar, Shiva Senthil</creatorcontrib><creatorcontrib>Mohamad, Maya</creatorcontrib><creatorcontrib>Mackay, Alan</creatorcontrib><creatorcontrib>Stanek, Joseph</creatorcontrib><creatorcontrib>Rodriguez, Diana</creatorcontrib><creatorcontrib>Palmer, Joshua</creatorcontrib><creatorcontrib>Leach, James</creatorcontrib><creatorcontrib>Mikael, Leonie</creatorcontrib><creatorcontrib>Thomas, Diana</creatorcontrib><creatorcontrib>Fuller, Christine</creatorcontrib><creatorcontrib>Boué, Daniel</creatorcontrib><creatorcontrib>Pierson, Christopher</creatorcontrib><creatorcontrib>Breneman, John</creatorcontrib><creatorcontrib>Li, Xiao-Nan</creatorcontrib><creatorcontrib>Salloum, Ralph</creatorcontrib><creatorcontrib>Ashley, David</creatorcontrib><creatorcontrib>de Blank, Peter</creatorcontrib><creatorcontrib>Hwang, Eugene</creatorcontrib><creatorcontrib>Leary, Sarah</creatorcontrib><creatorcontrib>Plant, Ashley</creatorcontrib><creatorcontrib>Fisher, Michael</creatorcontrib><creatorcontrib>Chi, Susan</creatorcontrib><creatorcontrib>Murala, Mythili</creatorcontrib><creatorcontrib>Weetall, Marla</creatorcontrib><creatorcontrib>Rance, Mark</creatorcontrib><creatorcontrib>Baird, John</creatorcontrib><creatorcontrib>D’Silva, Dhiren</creatorcontrib><creatorcontrib>O’Keefe, Kylie</creatorcontrib><creatorcontrib>Leonard, Jeffrey</creatorcontrib><creatorcontrib>Stewart, Clinton</creatorcontrib><creatorcontrib>Jones, Chris</creatorcontrib><creatorcontrib>Mardis, Elaine</creatorcontrib><creatorcontrib>Fouladi, Maryam</creatorcontrib><creatorcontrib>Drissi, Rachid</creatorcontrib><title>PATH-13. MOLECULAR AND BIOLOGY CORRELATIVE RESULTS FROM THE PHASE 1B TRIAL OF UNESBULIN (PTC596) WITH RADIOTHERAPY IN CHILDREN NEWLY-DIAGNOSED WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract BACKGROUND Within the CONNECT1702 trial of unesbulin (tubulin-binding agent causing BMI-1 modulation) with radiotherapy in patients with DIPG/HGG, tumor tissue was analyzed at diagnosis and/or autopsy for biology correlatives, enabling comprehensive, longitudinal molecular characterization. METHODS Whole genome sequencing, RNA-sequencing, and Western blot analyses were performed on tumor, normal brain, and peripheral blood mononuclear cells (PBMCs). RESULTS Tumor tissue from diagnosis (n=11) and/or autopsy (n=7) was analyzed for 16 patients (DIPG=9; HGG=7). Western blot analyses demonstrated 1) BMI-1 overexpression in baseline tumor compared to normal brain and 2) primary on-target effect of BMI1-modulation causing M-phase mitotic arrest when comparing pre- and post-treated PBMCs (increased H3S10-phosphorylation). Among 9 DIPG patients, alterations in the following genes were identified: H3-3A (H3.3) (n=5), H3C2 (H3.1) (n=2, both with co-occurring ACVR1 and PIK3CA mutations), TP53 (n=5), ATRX (n=2), and PPM1D (n=2). Tumors from two longer DIPG survivors were H3.1-, ACVR1-mutant (overall survival [OS]=26 months) and MET-amplified (OS=18 months); one patient with H3.3K27M-DIPG had germline MSH6 mutation (Lynch syndrome) (OS=12.6 months). Among 7 HGG patients, alterations in the following genes were identified: H3-3A (n=5), TP53 (n=3), NF1 (n=3), PDGFRA (n=1), EGFR (n=1), and PIK3CA (n=1). A BRAFV600E mutation was observed in the thalamic HGG patient (H3.3K27M) with greatest progression-free survival (&gt;23 months). Early leptomeningeal metastases occurred in one DIPG patient with BCOR alteration and one HGG patient, with MYCN amplification identified in the spinal metastasis, but not intracranial disease. From gene set enrichment analyses, pathways enriched in patients with longer survival included telomerase regulation and ATP synthesis, whereas pathways enriched in patients with shorter survival included interneuron development, neuron semaphorin signaling, and gamma aminobutyric signaling. CONCLUSIONS Comprehensive molecular profiling of diagnostic and post-mortem tumor tissue provides valuable early biological insight, elucidating potential genomic biomarkers predictive of outcome and response to M-phase alteration and BMI-1 modulation in DIPG/HGG.</description><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNkUGPmzAQhWnVSt1u-wt6mWNyIItNcEhvjjFg1bGRMY1yQiQYqVWbrIL2sP--Toi01_rikWa-p_f0guAbihYoWsdPJ_dyPh2fTufOIZIsohXC74MHlOA4TFJCPtxmHKYJWn0KPo_j7yjCKCHo4V1YUVuGKF7AVkvOGkkNUJXBRmipiz0wbQyX1IqfHAyvG2lryI3egi05VCWtOaANWCOoBJ1Do3i9aaRQMKssS9ZkDjthSzA0E9ojhlZ78FtWCpkZrkDxndyHmaCF0jXPputM5HnjlYXywqoWDCqtrFAcCin0lsIsE1UxvxktRVGGhdd_W5ZFMf8O1PuttLFvdpmWkm60mdIobnfa_IBcGz83RodasXtoH0Awn-iWq4YZ00pxZudfgo9D92d0X-__Y2BzblkZeuwKhMc0xmHvXNp3Q-QOJMJLRw7xgIlbJus06pb4iIc4WSFCop70uO_jFXLYP7dGx-SQ9gccPwbxJHu8nMfx4ob2-fLrb3d5bVHUXgtvp8Lbe-HttXBPLSbq_PL8X8A_urGaKA</recordid><startdate>20241111</startdate><enddate>20241111</enddate><creator>Lazow, Margot</creator><creator>Baxter, Patricia</creator><creator>Kumar, Shiva Senthil</creator><creator>Mohamad, Maya</creator><creator>Mackay, Alan</creator><creator>Stanek, Joseph</creator><creator>Rodriguez, Diana</creator><creator>Palmer, Joshua</creator><creator>Leach, James</creator><creator>Mikael, Leonie</creator><creator>Thomas, Diana</creator><creator>Fuller, Christine</creator><creator>Boué, Daniel</creator><creator>Pierson, Christopher</creator><creator>Breneman, John</creator><creator>Li, Xiao-Nan</creator><creator>Salloum, Ralph</creator><creator>Ashley, David</creator><creator>de Blank, Peter</creator><creator>Hwang, Eugene</creator><creator>Leary, Sarah</creator><creator>Plant, Ashley</creator><creator>Fisher, Michael</creator><creator>Chi, Susan</creator><creator>Murala, Mythili</creator><creator>Weetall, Marla</creator><creator>Rance, Mark</creator><creator>Baird, John</creator><creator>D’Silva, Dhiren</creator><creator>O’Keefe, Kylie</creator><creator>Leonard, Jeffrey</creator><creator>Stewart, Clinton</creator><creator>Jones, Chris</creator><creator>Mardis, Elaine</creator><creator>Fouladi, Maryam</creator><creator>Drissi, Rachid</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20241111</creationdate><title>PATH-13. MOLECULAR AND BIOLOGY CORRELATIVE RESULTS FROM THE PHASE 1B TRIAL OF UNESBULIN (PTC596) WITH RADIOTHERAPY IN CHILDREN NEWLY-DIAGNOSED WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)</title><author>Lazow, Margot ; Baxter, Patricia ; Kumar, Shiva Senthil ; Mohamad, Maya ; Mackay, Alan ; Stanek, Joseph ; Rodriguez, Diana ; Palmer, Joshua ; Leach, James ; Mikael, Leonie ; Thomas, Diana ; Fuller, Christine ; Boué, Daniel ; Pierson, Christopher ; Breneman, John ; Li, Xiao-Nan ; Salloum, Ralph ; Ashley, David ; de Blank, Peter ; Hwang, Eugene ; Leary, Sarah ; Plant, Ashley ; Fisher, Michael ; Chi, Susan ; Murala, Mythili ; Weetall, Marla ; Rance, Mark ; Baird, John ; D’Silva, Dhiren ; O’Keefe, Kylie ; Leonard, Jeffrey ; Stewart, Clinton ; Jones, Chris ; Mardis, Elaine ; Fouladi, Maryam ; Drissi, Rachid</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c832-dee8daf0eb6024e6b3f26e45980a42c2f3571660d6d2dd371e2222e91c5b8db23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lazow, Margot</creatorcontrib><creatorcontrib>Baxter, Patricia</creatorcontrib><creatorcontrib>Kumar, Shiva Senthil</creatorcontrib><creatorcontrib>Mohamad, Maya</creatorcontrib><creatorcontrib>Mackay, Alan</creatorcontrib><creatorcontrib>Stanek, Joseph</creatorcontrib><creatorcontrib>Rodriguez, Diana</creatorcontrib><creatorcontrib>Palmer, Joshua</creatorcontrib><creatorcontrib>Leach, James</creatorcontrib><creatorcontrib>Mikael, Leonie</creatorcontrib><creatorcontrib>Thomas, Diana</creatorcontrib><creatorcontrib>Fuller, Christine</creatorcontrib><creatorcontrib>Boué, Daniel</creatorcontrib><creatorcontrib>Pierson, Christopher</creatorcontrib><creatorcontrib>Breneman, John</creatorcontrib><creatorcontrib>Li, Xiao-Nan</creatorcontrib><creatorcontrib>Salloum, Ralph</creatorcontrib><creatorcontrib>Ashley, David</creatorcontrib><creatorcontrib>de Blank, Peter</creatorcontrib><creatorcontrib>Hwang, Eugene</creatorcontrib><creatorcontrib>Leary, Sarah</creatorcontrib><creatorcontrib>Plant, Ashley</creatorcontrib><creatorcontrib>Fisher, Michael</creatorcontrib><creatorcontrib>Chi, Susan</creatorcontrib><creatorcontrib>Murala, Mythili</creatorcontrib><creatorcontrib>Weetall, Marla</creatorcontrib><creatorcontrib>Rance, Mark</creatorcontrib><creatorcontrib>Baird, John</creatorcontrib><creatorcontrib>D’Silva, Dhiren</creatorcontrib><creatorcontrib>O’Keefe, Kylie</creatorcontrib><creatorcontrib>Leonard, Jeffrey</creatorcontrib><creatorcontrib>Stewart, Clinton</creatorcontrib><creatorcontrib>Jones, Chris</creatorcontrib><creatorcontrib>Mardis, Elaine</creatorcontrib><creatorcontrib>Fouladi, Maryam</creatorcontrib><creatorcontrib>Drissi, Rachid</creatorcontrib><collection>CrossRef</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lazow, Margot</au><au>Baxter, Patricia</au><au>Kumar, Shiva Senthil</au><au>Mohamad, Maya</au><au>Mackay, Alan</au><au>Stanek, Joseph</au><au>Rodriguez, Diana</au><au>Palmer, Joshua</au><au>Leach, James</au><au>Mikael, Leonie</au><au>Thomas, Diana</au><au>Fuller, Christine</au><au>Boué, Daniel</au><au>Pierson, Christopher</au><au>Breneman, John</au><au>Li, Xiao-Nan</au><au>Salloum, Ralph</au><au>Ashley, David</au><au>de Blank, Peter</au><au>Hwang, Eugene</au><au>Leary, Sarah</au><au>Plant, Ashley</au><au>Fisher, Michael</au><au>Chi, Susan</au><au>Murala, Mythili</au><au>Weetall, Marla</au><au>Rance, Mark</au><au>Baird, John</au><au>D’Silva, Dhiren</au><au>O’Keefe, Kylie</au><au>Leonard, Jeffrey</au><au>Stewart, Clinton</au><au>Jones, Chris</au><au>Mardis, Elaine</au><au>Fouladi, Maryam</au><au>Drissi, Rachid</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PATH-13. MOLECULAR AND BIOLOGY CORRELATIVE RESULTS FROM THE PHASE 1B TRIAL OF UNESBULIN (PTC596) WITH RADIOTHERAPY IN CHILDREN NEWLY-DIAGNOSED WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2024-11-11</date><risdate>2024</risdate><volume>26</volume><issue>Supplement_8</issue><spage>viii180</spage><epage>viii180</epage><pages>viii180-viii180</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract BACKGROUND Within the CONNECT1702 trial of unesbulin (tubulin-binding agent causing BMI-1 modulation) with radiotherapy in patients with DIPG/HGG, tumor tissue was analyzed at diagnosis and/or autopsy for biology correlatives, enabling comprehensive, longitudinal molecular characterization. METHODS Whole genome sequencing, RNA-sequencing, and Western blot analyses were performed on tumor, normal brain, and peripheral blood mononuclear cells (PBMCs). RESULTS Tumor tissue from diagnosis (n=11) and/or autopsy (n=7) was analyzed for 16 patients (DIPG=9; HGG=7). Western blot analyses demonstrated 1) BMI-1 overexpression in baseline tumor compared to normal brain and 2) primary on-target effect of BMI1-modulation causing M-phase mitotic arrest when comparing pre- and post-treated PBMCs (increased H3S10-phosphorylation). Among 9 DIPG patients, alterations in the following genes were identified: H3-3A (H3.3) (n=5), H3C2 (H3.1) (n=2, both with co-occurring ACVR1 and PIK3CA mutations), TP53 (n=5), ATRX (n=2), and PPM1D (n=2). Tumors from two longer DIPG survivors were H3.1-, ACVR1-mutant (overall survival [OS]=26 months) and MET-amplified (OS=18 months); one patient with H3.3K27M-DIPG had germline MSH6 mutation (Lynch syndrome) (OS=12.6 months). Among 7 HGG patients, alterations in the following genes were identified: H3-3A (n=5), TP53 (n=3), NF1 (n=3), PDGFRA (n=1), EGFR (n=1), and PIK3CA (n=1). A BRAFV600E mutation was observed in the thalamic HGG patient (H3.3K27M) with greatest progression-free survival (&gt;23 months). Early leptomeningeal metastases occurred in one DIPG patient with BCOR alteration and one HGG patient, with MYCN amplification identified in the spinal metastasis, but not intracranial disease. From gene set enrichment analyses, pathways enriched in patients with longer survival included telomerase regulation and ATP synthesis, whereas pathways enriched in patients with shorter survival included interneuron development, neuron semaphorin signaling, and gamma aminobutyric signaling. CONCLUSIONS Comprehensive molecular profiling of diagnostic and post-mortem tumor tissue provides valuable early biological insight, elucidating potential genomic biomarkers predictive of outcome and response to M-phase alteration and BMI-1 modulation in DIPG/HGG.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noae165.0712</doi></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii180-viii180
issn 1522-8517
1523-5866
language eng
recordid cdi_crossref_primary_10_1093_neuonc_noae165_0712
source Oxford University Press Journals All Titles (1996-Current)
title PATH-13. MOLECULAR AND BIOLOGY CORRELATIVE RESULTS FROM THE PHASE 1B TRIAL OF UNESBULIN (PTC596) WITH RADIOTHERAPY IN CHILDREN NEWLY-DIAGNOSED WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T06%3A37%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PATH-13.%20MOLECULAR%20AND%20BIOLOGY%20CORRELATIVE%20RESULTS%20FROM%20THE%20PHASE%201B%20TRIAL%20OF%20UNESBULIN%20(PTC596)%20WITH%20RADIOTHERAPY%20IN%20CHILDREN%20NEWLY-DIAGNOSED%20WITH%20DIFFUSE%20INTRINSIC%20PONTINE%20GLIOMA%20(DIPG)%20AND%20HIGH-GRADE%20GLIOMA%20(HGG):%20A%20REPORT%20FROM%20THE%20COLLABORATIVE%20NETWORK%20FOR%20NEURO-ONCOLOGY%20CLINICAL%20TRIALS%20(CONNECT)&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Lazow,%20Margot&rft.date=2024-11-11&rft.volume=26&rft.issue=Supplement_8&rft.spage=viii180&rft.epage=viii180&rft.pages=viii180-viii180&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noae165.0712&rft_dat=%3Coup_cross%3E10.1093/neuonc/noae165.0712%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noae165.0712&rfr_iscdi=true